Home infusion providers can successfully administer monoclonal antibody (mAb) therapy to COVID-19 patients in long-term care facilities with minimal side effects, according to a new report released by the National Home Infusion Association (NHIA).
However, barriers to reimbursement continue to pose challenges for home infusion providers seeking to continue to provide mAb therapy to their patients after the conclusion of the pilot project, according to association officials.
NHIA